双膦酸盐治疗骨纤维结构不良骨痛的研究进展  

Bisphosphonates in bone pain of fibrous dysplasia

作　　者：杨美平 许树柴[2] 刘岩[2] YANG Mei-ping;XU Shu-chai;LIU Yan(Department of Orthopaedics,The Second Clinical Medical College of Guangzhou University of Traditional Chinese Medicine,Guangzhou,Guangdong,510405,China)

机构地区：[1]广州中医药大学第二临床医学院,广东510405 [2]广州中医药大学附属广东省中医院骨科,广东520105

出　　处：《中国骨与关节杂志》2022年第2期137-141,共5页Chinese Journal of Bone and Joint

摘　　要：一、概述骨纤维结构不良(fibrous dysplasia,FD)是一种罕见的先天性骨病,由GNAS基因(鸟嘌呤核苷酸结合蛋白,α刺激活性多肽)突变所致[1],主要的组织学特征是异常增殖的纤维组织和编织骨取代了正常骨[2]。FD的临床表现具有异质性:有些患者症状轻甚至无症状,通常因偶然体检而发现,有些则表现为严重损害如骨痛、畸形等[3-4]。Fibrous dysplasia,caused by mutations of the GNAS gene,is a rare congenital bone disease.Nearly half of patients are suffering from bone pain,which is a major harm affecting the life quality of FD patients.It is reported that bisphosphonates can relieve bone pain and reduce pathological fracture risk in patients with bone metastasis or Paget disease.Bisphosphonates may play a similar role in FD patients.This article reviews the therapeutic potential of bisphosphonates in relieving bone pain,improving bone strength and reducing pathological fractures in FD patients,aiming to provide references for FD drug treatment.

关 键 词：二膦酸盐类 骨疾病 骨纤维结构不良 综述 

分 类 号：R681.1[医药卫生—骨科学]